Efficacy and safety of cannabidiol oil in psoriasis: a randomized, double-blind, placebo-controlled trial

The management of psoriasis presents challenges, prompting many patients to seek alternative treatments. Cannabidiol (CBD) has demonstrated potential antioxidant and anti-inflammatory properties which may offer therapeutic benefits for skin conditions.

To evaluate the efficacy and safety of cannabidiol oil compared to placebo in chronic plaque psoriasis patients.

The randomized, double-blind, placebo-controlled trial enrolled 28 participants, who were administered either oral CBD oil 60 mg/day or placebo. The primary outcome was the Psoriasis Area and Severity Index (PASI) score. Secondary outcomes encompassed disease severity, quality of life, and sleep parameters. Safety was monitored through adverse events and laboratory assessments.

The CBD group did not demonstrate a significant improvement in PASI scores. However, there was a notable reduction in itch scores by Week 8, and sleep onset latency decreased by Week 6, although this effect was not sustained. Adverse events were mild to moderate in nature and similar across both groups.

The study duration may not fully capture the long-term effects, and the race and disease severity may limit the generalizability of the findings. A larger sample size is suggested for future studies.

Cannabidiol oil was well-tolerated; however, it did not result in a significant reduction in psoriasis severity. Temporary improvements in itch relief and sleep onset indicate that further research with higher doses and extended durations is warranted.